Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 162 With a Single Ascending Dose in Subjects With Chronic Hepatitis B Virus Infection

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hepatitis B surface antigen targeting antibody-Yangshengtang Co. Ltd (Primary)
Indications Hepatitis B
Focus Adverse reactions
Sponsors Zhejiang Yangshengtang Biotech Co., Ltd.

16 Jul 2024 Status changed from not yet recruiting to discontinued due to enrollment difficulty
19 Feb 2024 Planned initiation date changed from 12 Jan 2024 to 27 Feb 2024.
08 Dec 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com